Adverum Biotechnologies, Inc.
ADVM
$4.17
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -47.30% | -61.29% | -73.20% | -111.16% | 1.62% |
| Total Depreciation and Amortization | -47.75% | -44.04% | -31.49% | -19.72% | -41.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -62.64% | -68.90% | -38.02% | 121.04% | -34.39% |
| Change in Net Operating Assets | 332.84% | 277.71% | 108.60% | 330.86% | 258.27% |
| Cash from Operations | -33.10% | -95.36% | -84.00% | -32.45% | 11.66% |
| Capital Expenditure | 35.75% | -650.00% | -144.44% | 68.23% | 55.35% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 115.24% | 1,485.72% | 243.59% | 57.38% | -170.22% |
| Cash from Investing | 113.92% | 1,471.04% | 242.01% | 57.59% | -173.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -1.24% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 203.45% | -- | 43.98% | 100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 52.54% | 69.74% | -115.40% | -3.73% | -492.17% |